REPL - Replimune Group Inc

-

$undefined

N/A

(N/A)

Replimune Group Inc NasdaqGS:REPL Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Location: 500 Unicorn Park Drive, Woburn, MA, 01801, United States | Website: https://www.replimune.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

314.7M

Cash

483.8M

Avg Qtr Burn

-48.06M

Short % of Float

17.39%

Insider Ownership

4.51%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

PDUFA

Approval decision

RP2 + Opdivo Details
Cancer, Uveal melanoma

Phase 2/3

Data readout

RP1 + Opdivo Details
Cancer, Non-melanoma skin cancer

Phase 2

Update

RP1 + Libtayo (cemiplimab) Details
Cutaneous squamous cell carcinoma, Cancer

Phase 2

Update

Phase 2

Initiation

RP1 Details
Cancer, Cutaneous squamous cell carcinoma, Kidney transplantation, Liver transplant, Skin cancer

Phase 1/2

Data readout

RP2 +/- Opdivo Details
Solid tumor/s, Cancer, Breast cancer, Head and neck cancer, Lung cancer, Hepatocellular carcinoma

Phase 1

Update

(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details
Cancer, Colorectal cancer , Hepatocellular carcinoma

Failed

Discontinued

RP3 +/- Opdivo Details
Solid tumor/s, Cancer, Lung cancer, Breast cancer, Head and neck cancer

Failed

Discontinued

RP3 in comb w/std. of care Details
Cancer, Head and neck squamous cell carcinoma

Failed

Discontinued